Commodore Capital disclosed a buy of 400,161 shares of Spyre Therapeutics (NASDAQ:SYRE), totaling an estimated $10.46 million trade based on quarterly average pricing, as per a February 17, 2026, SEC filing. The company increased its position in Spyre Therapeutics by 400,161 shares during the fourth quarter, with the quarter-end stake value rising by $44.92 million. Top holdings post-filing include RLAY, ALKS, TYRA, XENE, and SYRE.
Shares of Spyre Therapeutics were priced at $35.95 as of February 17, 2026, up 62.9% over the past year, outperforming the S&P 500’s 13% gain in the same period. The company’s market capitalization stands at $2.17 billion, with a net income of ($148.97 million) and a one-year price change of 63%.
Spyre Therapeutics specializes in developing preclinical-stage monoclonal antibody therapeutics for inflammatory bowel disease, with lead programs including SPY001, SPY002, and multiple combination therapies in early-stage development. The company focuses on addressing unmet needs in the inflammatory bowel disease market by investing in R&D for proprietary biologic candidates.
Spyre Therapeutics has roughly $757 million in cash, cash equivalents, and marketable securities, with a cash runway expected into the second half of 2028. Despite a net loss of $62.5 million in the fourth quarter, the company’s balance sheet was strengthened by a $316 million October offering. With six proof-of-concept Phase 2 readouts expected in 2026, the company is focused on differentiated antibodies and combination biology.
Before investing in Spyre Therapeutics, consider that it was not among the 10 best stocks identified by The Motley Fool Stock Advisor analyst team. The top 10 stocks they selected could produce significant returns in the future, with Stock Advisor’s total average return being 904%, compared to the S&P 500’s 194%. Stay informed and join an investing community designed for individual investors.
Read more at Yahoo Finance: Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million